Pregabalin Capsule
Product Images NDC 68788-7523

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7523). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3da23e7c A3be 46cb B403 Da4fb78019db 00

Label for Pregabalin Capsules 100 mg, oral capsules by Preferred Pharmaceuticals, Inc., generic for Lyrica. The label specifies each capsule contains 100mg pregabalin. It includes dosage directions in English and Spanish, storage instructions, warnings, and barcode. The label also has fields for lot number, expiration date, and insurance information, with manufacturer listed as ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline for Pregabalin at different dosages (25 mg, 100 mg, 200 mg, each three times a day) compared to placebo. The lines show decreasing patient improvement as pain improvement percentage increases.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting the percent improvement in pain from baseline against the percent of patients improved. It compares two groups: patients taking Pregabalin 100 mg three times a day and those on placebo, with plotted lines showing higher improvement percentages for the Pregabalin group.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The graph depicts increasing patient improvement with higher Pregabalin dosages relative to placebo over a range of percent improvement in pain.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing their relative effectiveness in pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent improvement in pain from baseline on the x-axis against the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The lines show higher improvement percentages for both Pregabalin dosages compared to placebo.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two clinical studies labeled Study E1 and Study E3. The horizontal axis shows treatment groups including placebo and various pregabalin doses (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) with dosing frequency BID or TID. The vertical axis shows responder rates from 0% to 60%. Bars indicate increasing responder rates with higher pregabalin doses, with statistical significance noted versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph comparing median seizure reduction percentages versus dose (mg/day) for four studies labeled E1BD, E2TID, E3BD, and E3TID. The x-axis shows dose increments from 0 to 600 mg/day, and the y-axis shows seizure reduction from 0% to 60%. Significant p-values are noted at multiple dose points, indicating statistical relevance for seizure reduction compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph includes four plots comparing Pregabalin at daily doses of 300 mg, 450 mg, and 800 mg versus placebo, showing patient response rates across different levels of pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (likely loss to relapse), from 0% to 100%, and the x-axis shows days from 0 to 180. Two curves are shown: a solid line for Pregabalin with a higher survival rate over time and a dashed line for placebo with a lower survival rate.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 between Pregabalin and placebo groups. The x-axis represents percent improvement from baseline to week 12 BOCF, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 90. Two lines illustrate trends for Pregabalin and placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo from baseline to week 16 BOCF. The x-axis shows percent improved from baseline to week 16, and the y-axis represents the percent of subjects improved. The Pregabalin group shows a higher improvement rate compared to the Placebo group throughout the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A pharmacokinetic formula calculating creatinine clearance (CLcr) based on age, weight, serum creatinine level, with an adjustment factor for female patients. The equation is presented as age times weight divided by serum creatinine, multiplied by 0.85 for females.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular configuration with an amino group, carboxyl group, and isobutyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.